Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harold Varmus

Showing results (61-70 of 80) with videos related to

Pageof 8
Sort By:
Plos Genetics|October 25, 2016
Wild-Type U2AF1 Antagonizes the Splicing Program Characteristic of U2AF1-Mutant Tumors and Is Required for Cell SurvivalDennis Liang Fei, Hayley Motowski, Rakesh Chatrikhi, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 17, 2018
Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene <i>U2af1</i>Dennis Liang Fei, Tao Zhen, Benjamin Durham, et al.
Science (New York, N.Y.)|February 8, 2024
Lineage-specific intolerance to oncogenic drivers restricts histological transformationEric E Gardner, Ethan M Earlie, Kate Li, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 27, 2004
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinibWilliam Pao, Vincent Miller, Maureen Zakowski, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 14, 2024
Genome-wide CRISPR screens in spheroid culture reveal that the tumor suppressor LKB1 inhibits growth via the PIKFYVE lipid kinaseJohn R Ferrarone, Jerin Thomas, Arun M Unni, et al.
Biorxiv : the Preprint Server for Biology|October 31, 2023
LKB1 suppresses growth and promotes the internalization of EGFR through the PIKFYVE lipid kinaseJohn R Ferrarone, Jerin Thomas, Arun M Unni, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 6, 2016
Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinomaDavid G McFadden, Katerina Politi, Arjun Bhutkar, et al.
Plos One|May 10, 2007
Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4Jenifer L Marks, Michael D McLellan, Maureen F Zakowski, et al.
Cancer Discovery|February 19, 2014
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancerElza C de Bruin, Catherine Cowell, Patricia H Warne, et al.
Cancer Discovery|January 30, 2023
LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung AdenocarcinomaBenjamin D Stein, John R Ferrarone, Eric E Gardner, et al.
Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
Plos Genetics|October 25, 2016
Wild-Type U2AF1 Antagonizes the Splicing Program Characteristic of U2AF1-Mutant Tumors and Is Required for Cell SurvivalDennis Liang Fei, Hayley Motowski, Rakesh Chatrikhi, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 17, 2018
Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene <i>U2af1</i>Dennis Liang Fei, Tao Zhen, Benjamin Durham, et al.
Science (New York, N.Y.)|February 8, 2024
Lineage-specific intolerance to oncogenic drivers restricts histological transformationEric E Gardner, Ethan M Earlie, Kate Li, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 27, 2004
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinibWilliam Pao, Vincent Miller, Maureen Zakowski, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 14, 2024
Genome-wide CRISPR screens in spheroid culture reveal that the tumor suppressor LKB1 inhibits growth via the PIKFYVE lipid kinaseJohn R Ferrarone, Jerin Thomas, Arun M Unni, et al.
Biorxiv : the Preprint Server for Biology|October 31, 2023
LKB1 suppresses growth and promotes the internalization of EGFR through the PIKFYVE lipid kinaseJohn R Ferrarone, Jerin Thomas, Arun M Unni, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 6, 2016
Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinomaDavid G McFadden, Katerina Politi, Arjun Bhutkar, et al.
Plos One|May 10, 2007
Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4Jenifer L Marks, Michael D McLellan, Maureen F Zakowski, et al.
Cancer Discovery|February 19, 2014
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancerElza C de Bruin, Catherine Cowell, Patricia H Warne, et al.
Cancer Discovery|January 30, 2023
LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung AdenocarcinomaBenjamin D Stein, John R Ferrarone, Eric E Gardner, et al.
Pageof 8